Court dismisses lawsuit over drug imports

Share this article:

A U.S. district court judge has dismissed a lawsuit filed by several consumer groups that accused Pfizer, Merck GlaxoSmithKline and six other drugmakers of colluding to block American consumers from importing cheaper drugs from Canada.
The judge ruled that buying drugs in Canada for use in the U.S. is illegal, so an effort to stop it can't be a violation of federal antitrust law.
"Prescription drugs purchased in Canada by American consumers for personal use in the United States are misbranded if introduced into United States' commerce," and therefore are illegal, wrote U.S. District Judge Joan Erickson.
"The courts are not the proper forum to determine whether Canada or another country's prescription drug labels or symbols function in the same manner or offer the same protections as the United States' 'Rx only' symbol." Ericksen ruled.
A spokeswoman for GlaxoSmithKline told "(The judge's) finding that these medicines imported into the U.S. from Canada are illegal – that's really a very weighty decision for us. And the absolute dismissal of the federal antitrust claims is a very favorable outcome."
Other drugmakers named in the lawsuit include Abbott Laboratories, Eli Lilly, Novartis, Wyeth, Boehringer Ingelheim and AstraZeneca.
The consumer groups suing the drugmakers included individuals and groups including the Minnesota Senior Federation, United Senior Action of Indiana, the Massachusetts Senior Action Council and the Central Laborers Welfare Fund.


Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...